Search research articles
Contact Us
Filters
Showing results (21-30 of 29) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 29 results.
The American Journal of Cardiology
|
November 6, 2013
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease
Antonio M Gotto, Christopher P Cannon, Xiujiang Susie Li, et al.
Journal of Lipid Research
|
December 20, 2011
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib
Ronald M Krauss, Kathleen Wojnooski, Joseph Orr, et al.
The New England Journal of Medicine
|
November 19, 2010
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Christopher P Cannon, Sukrut Shah, Hayes M Dansky, et al.
Journal of Cardiovascular Pharmacology and Therapeutics
|
April 17, 2014
Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study
Antonio M Gotto, Uma Kher, Manash Shankar Chatterjee, et al.
Genetics
|
April 26, 2002
A phenotype-sensitizing Apoe-deficient genetic background reveals novel atherosclerosis predisposition loci in the mouse
Hayes M Dansky, Pei Shu, M Donavan, et al.
American Heart Journal
|
September 29, 2009
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib
Christopher P Cannon, Hayes M Dansky, Michael Davidson, et al.
Journal of Lipid Research
|
December 15, 2015
Evaluation of CETP activity in vivo under non-steady-state conditions: influence of anacetrapib on HDL-TG flux
David G McLaren, Stephen F Previs, Robert D Phair, et al.
European Journal of Pharmacology
|
April 29, 2014
Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques
Thomas P Roddy, David G McLaren, Ying Chen, et al.
The New England Journal of Medicine
|
May 25, 2017
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Frederick E Dewey, Viktoria Gusarova, Richard L Dunbar, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 29) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 29 results.
The American Journal of Cardiology
|
November 6, 2013
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease
Antonio M Gotto, Christopher P Cannon, Xiujiang Susie Li, et al.
Journal of Lipid Research
|
December 20, 2011
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib
Ronald M Krauss, Kathleen Wojnooski, Joseph Orr, et al.
The New England Journal of Medicine
|
November 19, 2010
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Christopher P Cannon, Sukrut Shah, Hayes M Dansky, et al.
Journal of Cardiovascular Pharmacology and Therapeutics
|
April 17, 2014
Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study
Antonio M Gotto, Uma Kher, Manash Shankar Chatterjee, et al.
Genetics
|
April 26, 2002
A phenotype-sensitizing Apoe-deficient genetic background reveals novel atherosclerosis predisposition loci in the mouse
Hayes M Dansky, Pei Shu, M Donavan, et al.
American Heart Journal
|
September 29, 2009
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib
Christopher P Cannon, Hayes M Dansky, Michael Davidson, et al.
Journal of Lipid Research
|
December 15, 2015
Evaluation of CETP activity in vivo under non-steady-state conditions: influence of anacetrapib on HDL-TG flux
David G McLaren, Stephen F Previs, Robert D Phair, et al.
European Journal of Pharmacology
|
April 29, 2014
Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques
Thomas P Roddy, David G McLaren, Ying Chen, et al.
The New England Journal of Medicine
|
May 25, 2017
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Frederick E Dewey, Viktoria Gusarova, Richard L Dunbar, et al.
Page
of 3